Key insights
- Novocure's stock experienced a significant decline following the announcement that its Phase 3 TRIDENT trial for glioblastoma failed to meet its primary endpoint of improved overall survival. While the therapy was found to be feasible and well-tolerated, the marginal difference in median survival between the early and maintenance start arms suggests limited efficacy, impacting investor sentiment and potentially future revenue projections for the company.
Investing.com -- Novocure (NASDAQ:NVCR) shares fell 10% after the company announced that its Phase 3 TRIDENT trial did not meet its primary endpoint of demonstrating a statistically significant increase in overall survival for patients with newly diagnosed glioblastoma.
The trial evaluated initiating Tumor Treating Fields therapy at the start of chemoradiation compared to initiating the therapy during the maintenance phase of treatment. In the intent-to-treat population, the Early Start Arm had a median overall survival of 17.7 months compared to 17.5 months in the Maintenance Start Arm, with a hazard ratio of 0.953 and p-value of 0.519.
TRIDENT enrolled 981 patients who were randomized shortly after surgery. The study demonstrated that early initiation of TTFields therapy was feasible and well-tolerated, with no new safety signals observed. Device-related safety was consistent with prior clinical studies of TTFields therapy in glioblastoma.
Survival results in both study arms showed one-, two-, and three-year survival rates in the Early Start Arm of 70.9%, 33.9%, and 22.5%, respectively. In the Maintenance Start Arm, the survival rates were 72.0%, 31.6%, and 18.4%, respectively.
The median patient age in the trial was 60 years. Baseline characteristics included 38% of patients with a KPS of 70 or 80, 39% with a methylated MGMT promoter, and 5% with IDH-mutant tumors. Approximately 25% of patients did not initiate the maintenance phase across both arms of the trial.
The results from TRIDENT have been accepted for presentation at the American Society for Radiation Oncology 2026 Annual Meeting.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ProPicks AI evaluates NVCR alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if NVCR is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?